74 results about "Sinus polyp" patented technology

Methods of treating a central airway obstruction (CAO), benign airway stenosis, asthma, chronic obstructive pulmonary disease (COPD), or an airway tumor in a human subject, methods of treating chronic rhinosinusitis (CRS) or chronic rhinosinusitis with nasal polyps (CRSwNP) in a human subject, methods of treating a eustachian tube disorder in a human subject, and devices and systems for performing the methods. A method of treating a central airway obstruction (CAO), benign airway stenosis, asthma, chronic obstructive pulmonary disease (COPD), or an airway tumor in a human subject includes inserting a drug-coated balloon catheter into a target site in a trachea, mainstem bronchus, bronchus intermedius, lobar bronchus, segmental bronchus, or sub-segmental bronchus, wherein the balloon is coated with a coating layer including the therapeutic agent and one or more additives. The therapeutic agent includes paclitaxel, sirolimus, or a derivative thereof. The method includes inflating the balloon to dilate the airway and deliver a therapeutic agent to the airway wall. The method includes deflating the balloon. The method also includes withdrawing the balloon catheter from the target site.

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The invention belongs to the technical field of biology, and particularly relates to a reagent and a kit for detecting eosinophilic granulocyte chronic sinusitis with nasal polyp. The detection reagent comprises the following components: a substance which is used for detecting the Galectin-10 protein (Charcot-Leyden Crystal, CLCs) in a crystalline state, and a detection reagent which is used for detecting the Galectin-10 protein (Charcot-Leyden Crystal, CLCs) in the crystalline state. The reagent for detecting CLCs comprises a mixture of eosin, glacial acetic acid and water. The mass volume ratio of eosin to glacial acetic acid is 1: (1-50) g / mL, and the volume ratio of glacial acetic acid to water is 1: (2-100). According to the invention, the reagent capable of efficiently detecting the CLCs is found for the first time, and the CLCs is a biomarker of the eosinophilic chronic sinusitis with nasal polyp, so that the detection reagent for the eosinophilic chronic sinusitis with nasal polyp is provided. By detecting CLCs, eosinophilic granulocyte chronic sinusitis with nasal polyp can be predicted, and the method is simple, convenient and fast and has good prediction performance.

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

The invention discloses application of a TGM2 inhibitor in treatment of chronic sinusitis with nasal polyp, asthma and fibrosis complications thereof. Through single cell transcriptome analysis, it is found that the TGM2 is specifically and highly expressed in a macrophage subset (Tgm < 2 + > macrophage) in a CRSwNP sample with asthma, and the TGM2 protein expression level is significantly and positively correlated with the clinical severity of diseases such as CRSwNP and asthma; animal experiments verify that pathological injuries of the nasal cavity and the lung of a Tgm2-knocked-out mouse type 2 inflammation model are relieved, the inflammation of the upper and lower respiratory tracts of the mouse and the fibrosis level of the lung tissue can be remarkably relieved by adopting a small molecule drug ERW1041E for nasal drop administration, and the safety is good; the invention provides a brand-new treatment strategy for patients with diseases related to type 2 inflammation, and has remarkable clinical transformation value and market prospect.

The invention discloses a method for predicting the clinical outcome of treatment of patients with chronic sinusitis with nasal polyp (CRSwNP) by omphizumab according to the baseline expression level of cytokines in serum and application of the omphizumab. The research finds that the baseline expression levels of CCL-3 and CCL-4 in the serum of a patient can be used for predicting the clinical outcome of SNOT-22 symptom score improvement of a CRSwNP patient treated by aumaszumab for the first time; the baseline expression level of IL-8 in serum can be used for predicting the clinical outcome of nasal obstruction symptom improvement in treatment of a CRSwNP patient by the omaszumab; the baseline expression level of EGF in serum can be used for predicting the clinical outcome of improvement of the facial pain symptom of a CRSwNP patient treated by the omaszumab.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

Provided herein are methods and uses of antibodies that specifically bind human IL-13 ("anti-IL-13 antibodies") for the treatment of chronic rhinosinusitis with nasal polyps.

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

The present disclosure relates to pharmaceutical compositions comprising from about 100 mg to about 300 mg of an antigen binding protein which binds to IL-5. Compositions and antigen binding proteins of the disclosure are useful in the treatment of IL-5 mediated diseases, such as EGPA, HES, CRSsNP and CRSwNP, and can be administered about once every 6 months.

The present invention discloses a composition for improving rhinitis symptoms and nasal cleaning, as well as its preparation method and application. The composition comprises, by weight, 0.1 to 7 parts of yeast β-glucan and 0.1 to 6 parts of mussel mucin. The present invention prepares a composition for improving rhinitis symptoms and nasal cleaning by rationally combining ultra-low molecular weight yeast β-glucan, low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan, high molecular weight yeast β-glucan, and mussel mucin. The composition can be effectively used for nasal cleaning of patients with nasal diseases such as acute rhinitis, chronic rhinitis, allergic rhinitis, nasal polyps, sinusitis, etc., and can also be used for nasal cleaning after nasal tumor surgery or chemotherapy.

1. The name of the product of this design: electric nasal cleaner. 2. Purpose of the product with this appearance design: used for cleaning patients with nasal diseases such as acute and chronic rhinitis, allergic rhinitis, nasal polyps, sinusitis, etc., and also for nasal cleaning after nasal surgery and radiotherapy and daily nasal care. 3. The design key point of this appearance design product lies in the shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

150mg / mL omalizumab formulation for use in a method of treatment of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, wherein the omalizumab is administered subcutaneously by a syringe.

The invention belongs to the technical field of medicine, and discloses a medicinal sponge sheet for inhibiting growth of nasal polyp, the medicinal sponge sheet is composed of a medical grade absorptive gelatin sponge base material, triamcinolone acetonide and hydroxypropyl methyl cellulose, the medicinal sponge sheet adopts the medical gelatin base material with the porosity of 95% and the water absorption expansion rate of less than or equal to 30%, the size is 60mm * 20mm * 5mm, each sheet loads 60mg of triamcinolone acetonide, and the hydroxypropyl methyl cellulose is added into the medicinal sponge sheet. And 10% of hydroxypropyl methyl cellulose with the molecular weight of 35000 Da and the viscosity of 700 mPa.s is supplemented to construct a slow release system. Efficient and safe treatment of chronic nasosinusitis with nasal polyp is achieved through multi-dimensional innovative design, the three-dimensional interpenetrating pore structure of the medical gelatin base material provides an ideal carrier for drug release, 60%-70% of triamcinolone acetonide is continuously released within 7 days through the gradient slow release technology, a local high-concentration microenvironment is constructed, and the effect of treating chronic nasosinusitis with nasal polyp is achieved. The device directly acts on the polyp root to block an inflammation cascade reaction; in the formula, hydroxypropyl methyl cellulose is used as a core slow-release carrier.

The invention discloses application of lauromacrogol in preparation of a medicine for treating nasal polyp, and belongs to the technical field of medicines. The invention discloses an application of lauromacrogol in preparation of a medicine for treating nasal polyp. When lauromacrogol is used for treating nasal polyp, the nasal polyp can be reduced, and clinical symptoms can be eliminated. According to clinical data statistics, the lauromacrogol is adopted to treat nasal polyp, the cure rate is 89.56%, the improvement rate is 10.44%, and no recurrent symptoms occur. The invention creatively provides a new application of lauromacrogol, and the lauromacrogol is used for preparing the medicine for treating nasal polyp, and is definite in effect, small in adverse reaction and worthy of popularization and application.

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The present disclosure relates generally to methods of treating chronic sinusitis with or without nasal polyp using antibodies specific for thymic stromal lymphopoietin (TSLP).

This invention relates to an antisense oligonucleotide targeting the interleukin-4 receptor and its applications. The antisense oligonucleotide (ASO) molecule is 16-22 bases in length and specifically pairs with a specific region of the target gene (interleukin-4 receptor). The ASO is used to treat diseases related to IL-4Rα, including but not limited to asthma (including eosinophilic types), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, nodular prurigo, urticaria, COPD, bullous pemphigoid, pruritus, and gastritis.

The invention belongs to the technical field of biological stem cells, and particularly relates to a method for establishing an induced pluripotent stem cell line by using a clinical waste nasal polyp tissue and application of the induced pluripotent stem cell line. According to the invention, the nasal polyp tissue is cultured into a cell line capable of passage by using a tissue adherence method, and the cell line is identified to have the characteristics of fibroblasts; according to the invention, a nasal polyp-derived cell line is successfully established, and compared with a donor nasal polyp cell line, the invention does not observe that the nasal polyp-derived iPSC has any new mutation in P3, including cancer-related mutation and various mutation types. The P8 mutation number of the iPSC is slightly increased, the mutation numbers of blank mutants and chromosomes 1, 11, 17 and 20 are slightly increased, and the genome stability and safety of further application are not affected. The results show that the stable iPSC system can be constructed by the method, the gene mutation is less, and the early passage of the nasal polyp-derived iPSC can be used for stem cell treatment.

This disclosure provides a method, device, and storage medium for identifying the spatial aggregation features of immune cells in nasal polyps, relating to the field of data processing technology. The implementation scheme is as follows: A nasal polyp pathological slide is segmented into multiple pathological sub-images; positive immune cells are identified in each pathological sub-image to obtain the sub-image coordinates of each positive immune cell in each pathological sub-image; based on the positional information of each pathological sub-image on the nasal polyp pathological slide, the sub-image coordinates of each positive immune cell in each pathological sub-image are mapped onto the nasal polyp pathological slide to obtain the full-map coordinates of each positive immune cell in the nasal polyp pathological slide; based on the full-map coordinates of each positive immune cell in the nasal polyp pathological slide, cluster analysis is performed on the positive immune cells in the nasal polyp pathological slide to obtain the spatial aggregation features of immune cells in the nasal polyp tissue in the nasal polyp pathological slide. This improves the accuracy of the spatial aggregation features of immune cells in nasal polyps.

The present invention relates to a method for inducing the differentiation of human nasal mucosa mesenchymal stem cells into neural stem cells in batches based on 3D culture, the method comprising the following steps: (1) obtaining human nasal mucosa mesenchymal stem cells using human nasal polyps as a tissue source; (2) 3D culturing the human nasal mucosa mesenchymal stem cells and inducing their differentiation into neural stem cells in batches. The present invention provides a method for inducing the differentiation of human nasal mucosa mesenchymal stem cells into neural stem cells, and achieves batch production based on 3D culture. Therefore, the present invention provides a cell preparation method for treating neurodegenerative diseases such as Parkinson's disease caused by neuronal loss.

The invention relates to the field of biological medicine, in particular to application of AREG in chronic sinusitis with nasal polyp eosinophilic inflammation. According to the invention, the nasal epithelial cell, especially the basal cell, is found for the first time, is a cell source of the AREG and is also one of important target cells acted by the AREG. AREG promotes proliferation of epithelial basal cells and inhibits differentiation of the basal cells into cilia cells, resulting in structural abnormality and function impairment of human CRSwNP tissue epithelial barriers. The AREG chemotactices and activates human peripheral blood eosinophilic granulocytes, and the receptor EGFR antagonist Erlotinib of the AREG can antagonize the effect of the AREG on the eosinophilic granulocytes. The AREG secreted by neutralizing epithelial cells or other inflammatory cells can effectively relieve the eosinophilic inflammatory reaction of the nasal mucosa of the CRSwNP mouse model and recover the damaged epithelial barrier function of the nasal mucosa of the mouse. It is proved that when the neutralizing antibody of AREG or EGFR or shRNA is used as the antagonist, the eosinophilic inflammatory response of CRSwNP can be relieved by inhibiting the effect of AREG.

Disclosed herein are antigen binding proteins, e.g. an antibody, which bind to IL-5, for use in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), wherein the nasal polyps score and / or mean nasal obstruction score is improved.

The invention belongs to the field of medical diagnosis, and particularly provides a biomarker for predicting children chronic sinusitis with nasal polyp relapse and application of the biomarker. The invention discloses the biological marker ITGAM and / or FCGR3B related to children chronic sinusitis with nasal polyp relapse for the first time, and experiments prove that whether a child patient suffers from nasal polyp relapse or not can be accurately predicted by detecting the expression condition of ITGAM and / or FCGR3B in nasal polyp tissues of the child patient suffering from chronic sinusitis with nasal polyp, so that the risk of relapse of nasal polyp is reduced, and the risk of relapse of nasal polyp is reduced. Therefore, the follow-up visit frequency and medication after the operation can be adjusted according to the recurrence probability of nasal polyp of the sick child, and the method has extremely high guidance value for postoperative prognosis of the sick child.

A set of antisense oligonucleotides specifically inhibiting thymic stromal lymphopoietin and the use thereof. The antisense oligonucleotide molecules have a length of 16-20 bases. The antisense oligonucleotide molecules have the following use: (1) in the preparation of a preparation for inhibiting the expression level of thymic stromal lymphopoietin; or (2) in the treatment of asthma, atopic dermatitis, chronic obstructive pulmonary disease, sinusitis, and nasal polyps.

A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg / mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.

The invention provides a nasal polyp pathological section image recognition method and device, electronic equipment and a storage medium, and relates to the technical field of artificial intelligence and data processing. According to the implementation scheme, a domain generalization model is adopted to perform domain generalization on a nasal polyp pathological section image under a first visual field of a first detection object, and a nasal polyp pathological domain invariant feature map is obtained; a cell classification model and a tissue region segmentation model are adopted to carry out cell category classification and tissue region segmentation on the nasal polyp pathological domain invariant feature map to obtain the cell type of each cell in the nasal polyp pathological domain invariant feature map, an epithelial region, a blood vessel region and a gland region, and statistics is carried out according to the cell type, the epithelial region, the blood vessel region and the gland region. And determining the nasal polyp inflammation type of the first detection object according to a statistical result. Therefore, the recognition generalization and accuracy of the nasal polyp inflammation type are improved.

The invention relates to application of an NTSR1 inhibitor SR48692 in treatment of chronic sinusitis (CRS), in particular to application of the NTSR1 inhibitor SR48692 in treatment of chronic sinusitis (CRSwNP) accompanied with nasal polyp. Chronic sinusitis is a long-term inflammatory disease and is divided into a nasal polyp type and a nasal polyp-free type. By inhibiting a Wnt3a / beta-catenin signal channel, the SR48692 reduces abnormal deposition of an extracellular matrix and inhibits epithelial-mesenchymal transition (EMT), so that mucous membrane tissue remodeling is improved. Compared with a traditional treatment method, the SR48692 can reduce the recurrence rate of CRSwNP, provides a new treatment target for CRSwNP patients difficult to treat, and achieves a more lasting treatment effect.

150mg / mL omalizumab formulation for use in a method of treatment of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, wherein the omalizumab is administered subcutaneously by a syringe.

The invention discloses application of tiotropium bromide serving as a medicine for treating eosinophilic nasal polyp. The application comprises application of tiotropium bromide serving as a medicine for treating nasosinusitis with nasal polyp. The invention finds that tiotropium bromide can significantly improve the epithelium remodeling condition of eosinophilic sinusitis with nasal polyp, and can solve the problem of poor effect of treating eosinophilic sinusitis with nasal polyp aiming at T2 type inflammation at present in a manner of treating eosinophilic sinusitis with nasal polyp in a non-inflammatory way.